Fresenius SE & Co. KGaA Stock

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:18 2024-06-14 EDT 5-day change 1st Jan Change
29.56 EUR -1.24% Intraday chart for Fresenius SE & Co. KGaA -2.44% +5.31%

Financials

Sales 2024 * 22.16B 23.72B 32.59B Sales 2025 * 23.21B 24.84B 34.13B Capitalization 16.65B 17.82B 24.48B
Net income 2024 * 1.36B 1.45B 2B Net income 2025 * 1.72B 1.84B 2.54B EV / Sales 2024 * 1.31 x
Net Debt 2024 * 12.4B 13.27B 18.24B Net Debt 2025 * 11.69B 12.51B 17.19B EV / Sales 2025 * 1.22 x
P/E ratio 2024 *
12.3 x
P/E ratio 2025 *
9.48 x
Employees 190,863
Yield 2024 *
3.13%
Yield 2025 *
3.52%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Fresenius SE & Co. KGaA

1 day-1.24%
1 week-2.44%
Current month+0.96%
1 month+3.65%
3 months+18.24%
6 months+5.23%
Current year+5.31%
More quotes
1 week
29.30
Extreme 29.3
30.32
1 month
27.26
Extreme 27.26
30.68
Current year
24.32
Extreme 24.32
30.68
1 year
23.93
Extreme 23.93
31.22
3 years
19.69
Extreme 19.69
47.60
5 years
19.69
Extreme 19.69
51.54
10 years
19.69
Extreme 19.69
80.07
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 21-04-11
Director of Finance/CFO 44 18-12-31
Compliance Officer - 23-07-17
Members of the board TitleAgeSince
Director/Board Member 69 15-05-19
Chairman 69 19-12-31
Director/Board Member 63 16-05-12
More insiders
Date Price Change Volume
24-06-14 29.56 -1.24% 1,055,213
24-06-13 29.93 -0.40% 1,006,234
24-06-12 30.05 +2.11% 800,938
24-06-11 29.43 -2.42% 814,164
24-06-10 30.16 -0.46% 755,881

Delayed Quote Xetra, June 14, 2024 at 11:35 am

More quotes
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.56 EUR
Average target price
37.26 EUR
Spread / Average Target
+26.04%
Consensus